Impact of an e-Bug Educational Intervention on HPV Vaccine Uptake in Middle School Students
Condition(s) studied
Investigational drug(s) / intervention(s)
Consent for HPV vaccination: Consent for HPV vaccination
Study summary
This study is a non-interventional observational pilot analysis assessing the possible impact of an educational programme (e-Bug) on parental consent and HPV vaccination uptake during the 2023-2024 and 2024-2025 national school-based HPV vaccination campaigns in France. The study focuses on one middle school in the Alpes-Maritimes department where teachers and the school nurse had been previously trained on HPV and used e-Bug educational resources in class as part of routine health education. No research-related intervention was conducted, and the educational programme was not introduced or modified for the purpose of the study. Only aggregated and anonymised vaccination data were used. These data were routinely collected by the Regional Health Agency (ARS PACA) as part of the national vaccination programme and transmitted for analysis. Aggregated data from the pilot school were compared with departmental-level outcomes to describe whether an upstream educational approach may be associated with improved parental acceptance and higher HPV vaccination coverage. This study aims to contribute to the understanding of educational determinants of vaccine uptake in a real-life school setting without involving any participant recruitment or individual data collection.
Eligibility
Primary outcome measure(s)
- HPV vaccination uptake (1st and 2nd doses) in the pilot school compared with departmental data — From (start of 2023-2024 HPV vaccination campaign) to(end of 2024-2025)
e-Bug educational programme
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| CHU de NICE | Nice | Alpes Maritimes | Recruiting |
More Centre Hospitalier Universitaire de Nice trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07266857 on ClinicalTrials.gov ↗ ← All trials in France